Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. director Kainan Noga filed an initial ownership report showing a mix of ordinary shares, restricted share units and stock options in the company. One block of ordinary shares consists of restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Noga also holds stock options over 12,505, 50,000 and 10,000 ordinary shares with exercise prices of $64.6100, $17.6300 and $11.5200, expiring in 2031, 2032 and 2033, respectively. Some ordinary shares are held indirectly through I.B.L. Business Consulting Ltd., which is wholly owned by Noga.
Nano-X Imaging Ltd. disclosed the initial holdings of Chief Executive Officer Erez Meltzer. He directly holds 60,584 ordinary shares. He also holds stock options over 40,234 ordinary shares at an exercise price of $2.2100 per share expiring on February 11, 2030, and options over 300,000 ordinary shares at $23.8400 per share expiring on January 2, 2032, both fully vested and exercisable. Additional options over 150,000 ordinary shares at $11.5200 per share expire on April 16, 2034 and vest over four years, with 25% vested after one year and 6.25% vesting quarterly until April 16, 2028.
Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.
Nano-X Imaging Ltd. Chief Legal Officer Marina Gofman Feler filed an initial ownership report on 2026-03-18. She holds stock options over 15,000 ordinary shares at an exercise price of 17.6300 expiring on 2032-11-07, options over 10,000 shares at 17.6300 expiring on 2033-04-28, and options over 30,000 shares at 11.5200 expiring on 2033-05-23.
She also holds 20,000 ordinary shares underlying restricted share units granted on 2026-02-05, which vest 50% on the 12-month anniversary of the grant date and 50% on the 24-month anniversary. A separate line shows 26,316 additional ordinary shares held directly.
Nano-X Imaging Ltd. director Michael Jackman filed an initial ownership report showing his existing equity stake in the company. He holds stock options covering 19,624 ordinary shares at an exercise price of $2.2100 per share, expiring on November 25, 2029, which are fully vested and exercisable. He also reports direct ownership of ordinary shares, including shares underlying restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Nano-X Imaging Ltd. executive Ofir Koren, General Manager of the ARC Division, filed an initial ownership report showing direct holdings of ordinary shares and stock options. The filing lists stock options over 100,000, 25,000 and 33,500 ordinary shares with exercise prices of $49.6800, $17.6300 and $11.5200, expiring between 2031 and 2033. It also describes restricted share units granted in April 2024 and February 2026, which vest over time in scheduled installments.
Nano-X Imaging Ltd. executive Aharon Cohen Tamar, EVP & Chief Marketing Officer, reported his initial equity holdings. He directly holds ordinary shares, including 39,474 ordinary shares, and has 20,000 ordinary shares tied to restricted share units granted on February 5, 2026, which vest 50% after 12 months and 50% after 24 months.
He also holds stock options over ordinary shares: 33,000 at an exercise price of $49.68 expiring on January 18, 2031, 17,000 at $17.63 expiring on March 28, 2032, 8,000 at $17.63 expiring on May 16, 2032, and 55,000 at $11.52 expiring on May 23, 2033. The 2021 grant is fully vested, while the 2022 and 2023 grants vest in 16 equal quarterly installments.
NANO‑X IMAGING LTD filed a Form F-3 to register up to $100,000,000 of ordinary shares, warrants and debt securities for offer and sale from time to time. The registration permits primary offerings by the Company through underwriters, dealers, agents or direct sales after the registration becomes effective. The prospectus states proceeds are intended for funding research, general corporate purposes and other commercial efforts. As of December 31, 2025, 69,590,228 ordinary shares were issued and outstanding. The prospectus describes the Company’s Nanox System (Nanox.ARC, Nanox.CLOUD), FDA 510(k) clearances, CE mark, go‑to‑market plans in the U.S. and EU, AI and teleradiology assets, and that offerings will be detailed in prospectus supplements.
Nano-X Imaging Ltd. reports that the U.S. FDA has granted 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. TAP2D generates a 2D image directly from a 3D tomosynthesis scan, giving radiologists both 3D and 2D views from a single scan without additional radiation.
The company highlights this clearance as an important step in its regulatory strategy to position Nanox.ARC systems as primary diagnostic solutions and to work toward removing adjunctive use in the United States. The software enhancement can be delivered remotely to existing Nanox.ARC installations as part of ongoing imaging improvements.
Nano-X Imaging Ltd reports a registered direct offering to a single institutional investor of 3,826,530 ordinary shares at $3.92 per share. The transaction is expected to generate approximately $15.0 million in gross proceeds after deducting placement agent fees and other offering expenses payable by the company, which will be used for working capital and general corporate purposes.
Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as sole placement agent under a placement agency agreement. For 10 days after the placement agency agreement date, Nanox agreed not to issue or agree to issue additional ordinary shares or equivalents, or file new registration statements other than limited exceptions. Company officers and directors entered 30‑day lock-up agreements after the closing, restricting sales or other disposals of ordinary shares and related securities without the placement agent’s consent.